Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Identifieur interne : 000D47 ( PubMed/Curation ); précédent : 000D46; suivant : 000D48Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
Auteurs : D. Devos [France] ; P. Krystkowiak ; F. Clement ; K. Dujardin ; O. Cottencin ; N. Waucquier ; K. Ajebbar ; B. Thielemans ; M. Kroumova ; A. Duhamel ; A. Destée ; R. Bordet ; L. DefebvreSource :
- Journal of neurology, neurosurgery, and psychiatry [ 1468-330X ] ; 2007.
English descriptors
- KwdEn :
- Aged, Central Nervous System Stimulants (therapeutic use), Dose-Response Relationship, Drug, Fatigue, Female, Gait Disorders, Neurologic (drug therapy), Gait Disorders, Neurologic (etiology), Humans, Male, Methylphenidate (therapeutic use), Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Severity of Illness Index, Single-Blind Method, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Central Nervous System Stimulants, Methylphenidate.
- complications : Parkinson Disease.
- drug therapy : Gait Disorders, Neurologic, Parkinson Disease.
- etiology : Gait Disorders, Neurologic.
- Aged, Dose-Response Relationship, Drug, Fatigue, Female, Humans, Male, Middle Aged, Severity of Illness Index, Single-Blind Method, Treatment Outcome.
Abstract
Therapeutic management of gait disorders in patients with advanced Parkinson's disease (PD) can sometimes be disappointing, since dopaminergic drug treatments and subthalamic nucleus (STN) stimulation are more effective for limb-related parkinsonian signs than for gait disorders. Gait disorders could also be partly related to norepinephrine system impairment, and the pharmacological modulation of both dopamine and norepinephrine pathways could potentially improve the symptomatology.
DOI: 10.1136/jnnp.2006.100016
PubMed: 17098845
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D87
Links to Exploration step
pubmed:17098845Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.</title><author><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Institute of Predictive Medicine and Therapeutic Research, Lille University Medical Centre, Lille, France. d-devos@chru-lille.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Institute of Predictive Medicine and Therapeutic Research, Lille University Medical Centre, Lille</wicri:regionArea></affiliation></author><author><name sortKey="Krystkowiak, P" sort="Krystkowiak, P" uniqKey="Krystkowiak P" first="P" last="Krystkowiak">P. Krystkowiak</name></author><author><name sortKey="Clement, F" sort="Clement, F" uniqKey="Clement F" first="F" last="Clement">F. Clement</name></author><author><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name></author><author><name sortKey="Cottencin, O" sort="Cottencin, O" uniqKey="Cottencin O" first="O" last="Cottencin">O. Cottencin</name></author><author><name sortKey="Waucquier, N" sort="Waucquier, N" uniqKey="Waucquier N" first="N" last="Waucquier">N. Waucquier</name></author><author><name sortKey="Ajebbar, K" sort="Ajebbar, K" uniqKey="Ajebbar K" first="K" last="Ajebbar">K. Ajebbar</name></author><author><name sortKey="Thielemans, B" sort="Thielemans, B" uniqKey="Thielemans B" first="B" last="Thielemans">B. Thielemans</name></author><author><name sortKey="Kroumova, M" sort="Kroumova, M" uniqKey="Kroumova M" first="M" last="Kroumova">M. Kroumova</name></author><author><name sortKey="Duhamel, A" sort="Duhamel, A" uniqKey="Duhamel A" first="A" last="Duhamel">A. Duhamel</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name></author><author><name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R" last="Bordet">R. Bordet</name></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17098845</idno><idno type="pmid">17098845</idno><idno type="doi">10.1136/jnnp.2006.100016</idno><idno type="wicri:Area/PubMed/Corpus">000D87</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D87</idno><idno type="wicri:Area/PubMed/Curation">000D47</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.</title><author><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Institute of Predictive Medicine and Therapeutic Research, Lille University Medical Centre, Lille, France. d-devos@chru-lille.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Institute of Predictive Medicine and Therapeutic Research, Lille University Medical Centre, Lille</wicri:regionArea></affiliation></author><author><name sortKey="Krystkowiak, P" sort="Krystkowiak, P" uniqKey="Krystkowiak P" first="P" last="Krystkowiak">P. Krystkowiak</name></author><author><name sortKey="Clement, F" sort="Clement, F" uniqKey="Clement F" first="F" last="Clement">F. Clement</name></author><author><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name></author><author><name sortKey="Cottencin, O" sort="Cottencin, O" uniqKey="Cottencin O" first="O" last="Cottencin">O. Cottencin</name></author><author><name sortKey="Waucquier, N" sort="Waucquier, N" uniqKey="Waucquier N" first="N" last="Waucquier">N. Waucquier</name></author><author><name sortKey="Ajebbar, K" sort="Ajebbar, K" uniqKey="Ajebbar K" first="K" last="Ajebbar">K. Ajebbar</name></author><author><name sortKey="Thielemans, B" sort="Thielemans, B" uniqKey="Thielemans B" first="B" last="Thielemans">B. Thielemans</name></author><author><name sortKey="Kroumova, M" sort="Kroumova, M" uniqKey="Kroumova M" first="M" last="Kroumova">M. Kroumova</name></author><author><name sortKey="Duhamel, A" sort="Duhamel, A" uniqKey="Duhamel A" first="A" last="Duhamel">A. Duhamel</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name></author><author><name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R" last="Bordet">R. Bordet</name></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="eISSN">1468-330X</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Central Nervous System Stimulants (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Fatigue</term><term>Female</term><term>Gait Disorders, Neurologic (drug therapy)</term><term>Gait Disorders, Neurologic (etiology)</term><term>Humans</term><term>Male</term><term>Methylphenidate (therapeutic use)</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Severity of Illness Index</term><term>Single-Blind Method</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Central Nervous System Stimulants</term><term>Methylphenidate</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gait Disorders, Neurologic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Fatigue</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Single-Blind Method</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Therapeutic management of gait disorders in patients with advanced Parkinson's disease (PD) can sometimes be disappointing, since dopaminergic drug treatments and subthalamic nucleus (STN) stimulation are more effective for limb-related parkinsonian signs than for gait disorders. Gait disorders could also be partly related to norepinephrine system impairment, and the pharmacological modulation of both dopamine and norepinephrine pathways could potentially improve the symptomatology.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17098845</PMID><DateCreated><Year>2007</Year><Month>04</Month><Day>16</Day></DateCreated><DateCompleted><Year>2007</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>470-5</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Therapeutic management of gait disorders in patients with advanced Parkinson's disease (PD) can sometimes be disappointing, since dopaminergic drug treatments and subthalamic nucleus (STN) stimulation are more effective for limb-related parkinsonian signs than for gait disorders. Gait disorders could also be partly related to norepinephrine system impairment, and the pharmacological modulation of both dopamine and norepinephrine pathways could potentially improve the symptomatology.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the clinical value of chronic, high doses of methylphenidate (MPD) in patients with PD having gait disorders, despite their use of optimal dopaminergic doses and STN stimulation parameters.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Efficacy was blindly assessed on video for 17 patients in the absence of L-dopa and again after acute administration of the drug, both before and after a 3-month course of MPD, using a Stand-Walk-Sit (SWS) Test, the Tinetti Scale, the Unified Parkinson's Disease Rating Scale (UPDRS) part III score and the Dyskinesia Rating Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">An improvement was observed in the number of steps and time in the SWS Test, the number of freezing episodes, the Tinetti Scale score and the UPDRS part III score in the absence of L-dopa after 3 months of taking MPD. The L-dopa-induced improvement in these various scores was also stronger after the 3-month course of MPD than before. The Epworth Sleepiness Scale score fell dramatically in all patients. No significant induction of adverse effects was found.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Chronic, high doses of MPD improved gait and motor symptoms in the absence of L-dopa and increased the intensity of response of these symptoms to L-dopa in a population with advanced PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devos</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute of Predictive Medicine and Therapeutic Research, Lille University Medical Centre, Lille, France. d-devos@chru-lille.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krystkowiak</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Clement</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Cottencin</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Waucquier</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ajebbar</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Thielemans</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kroumova</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Duhamel</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Destée</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bordet</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Defebvre</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>207ZZ9QZ49</RegistryNumber><NameOfSubstance UI="D008774">Methylphenidate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Aug;18(8):872-83</RefSource><PMID Version="1">12889076</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2006 May;77(5):579-84</RefSource><PMID Version="1">16614016</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2003 Nov 13;349(20):1925-34</RefSource><PMID Version="1">14614167</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2003 Nov;184(1):9-13</RefSource><PMID Version="1">14637071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2004 Jun;55(6):766-73</RefSource><PMID Version="1">15174010</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacotherapy. 2004 Aug;24(8):1020-36</RefSource><PMID Version="1">15338851</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychol Rep. 1973 Jun;32(3):783-92</RefSource><PMID Version="1">4704758</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Psychiatry. 1979 Apr;134:382-9</RefSource><PMID Version="1">444788</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52</RefSource><PMID Version="1">2841426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Gerontol. 1990 Nov;45(6):P239-43</RefSource><PMID Version="1">2229948</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>No To Shinkei. 1991 Mar;43(3):263-8</RefSource><PMID Version="1">1907469</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 1991 Dec;14(6):540-5</RefSource><PMID Version="1">1798888</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1992;7(1):2-13</RefSource><PMID Version="1">1557062</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2000 Jul;15(4):692-8</RefSource><PMID Version="1">10928580</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2001 Jan 15;21(2):RC121</RefSource><PMID Version="1">11160455</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2001 Jul-Aug;24(4):208-13</RefSource><PMID Version="1">11479391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2001 Jul;16(4):708-13</RefSource><PMID Version="1">11481696</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CNS Drugs. 2001;15(6):495-500; discussion 501-3</RefSource><PMID Version="1">11524026</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Brain Res. 2002 Mar 10;130(1-2):79-83</RefSource><PMID Version="1">11864721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Neurol Neurosci Rep. 2002 Jul;2(4):310-6</RefSource><PMID Version="1">12044250</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2003 Jan;60(1):80-4</RefSource><PMID Version="1">12533092</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Park Dis Dement Sect. 1993;5(1):27-34</RefSource><PMID Version="1">8439390</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1994 Jul;44(7 Suppl 6):S29-34</RefSource><PMID Version="1">8047258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1994 Jul;9(4):390-4</RefSource><PMID Version="1">7969204</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 1997;104(11-12):1215-28</RefSource><PMID Version="1">9503267</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res Brain Res Rev. 1998 May;26(2-3):148-53</RefSource><PMID Version="1">9651511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1998 Oct;155(10):1325-31</RefSource><PMID Version="1">9766762</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 1999 Feb;288(2):798-804</RefSource><PMID Version="1">9918591</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Pharmacol. 2005 Feb;5(1):87-93</RefSource><PMID Version="1">15661631</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep Med Rev. 2005 Jun;9(3):185-200</RefSource><PMID Version="1">15893249</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 2005 Jun 1;57(11):1397-409</RefSource><PMID Version="1">15950014</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Med Assoc. 2005 Oct;97(10 Suppl):11S-16S</RefSource><PMID Version="1">16350601</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res Bull. 2006 Feb 15;68(6):393-405</RefSource><PMID Version="1">16459193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2006 Jan-Feb;29(1):15-7</RefSource><PMID Version="1">16518128</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Brain Res. 2003 Oct 17;145(1-2):7-15</RefSource><PMID Version="1">14529800</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020233" MajorTopicYN="N">Gait Disorders, Neurologic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008774" MajorTopicYN="N">Methylphenidate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC2117830</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17098845</ArticleId><ArticleId IdType="pii">jnnp.2006.100016</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2006.100016</ArticleId><ArticleId IdType="pmc">PMC2117830</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000D47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:17098845
|texte= Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17098845" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |